Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6244 plus dacarbazine versus dacarbazine alone in first-line BRAF-mutant advanced melanoma
2008-006344-19Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in melanoma, cutaneous melanoma (CM) and melanoma of unknown primary (MUP) comparing selumetinib + dacarbazine with dacarbazine alone (2 arms). Primary endpoint: Overall Survival. Started Apr 2009; status: completed.
02
Drugs
selumetinibdacarbazine
03
Conditions
melanomacutaneous melanoma (CM)melanoma of unknown primary (MUP)
Beyond the preview
Go deeper on 2008-006344-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006344-19.